The migration and invasion inhibitor protein (MIIP, also known as IIp45) was discovered as a negative regulator of cell migration and invasion in glioma. Our previous studies have shown that the MIIP protein was reduced or undetectable in some tissue samples obtained from patients with glioblastoma. The significance of MIIP in gliomagenesis is unknown. In this study, we report that MIIP has an important role in the inhibition of gliomagenesis and attenuation of mitotic transition. Increased MIIP expression levels inhibited colony formation and cell growth of glioma cell lines in vitro, whereas decreased expression by specific small interfering RNA for MIIP resulted in increased cell growth. Expression of MIIP in a glial-specific mouse model blocked glioma development and progression, thus showing that MIIP is an inhibitor of gliomagenesis. Furthermore, we show that MIIP attenuates mitotic transition and results in increased mitotic catastrophe. The biochemical mechanism of MIIP in this process is associated with its regulation of anaphase-promoting complex (APC/C) activity. MIIP interacts directly with Cdc20, and the interaction of MIIP with Cdc20 inhibits APC/C-mediated degradation of cyclin B1. Thus, MIIP attenuates mitotic transition and increases mitotic catastrophe, thereby inhibiting glioma development and progression.
Introduction
Diffuse gliomas comprise the most common and the most aggressive type of human primary brain tumor. The incidence of glioma has increased during the last few decades (Hoffman et al., 2006) . Patients with the most advanced and unfortunately the most frequent type of glioma, glioblastoma multiforme, have a meager median survival of less than a year, and this has not improved significantly over the past five decades (Maher et al., 2001; Behin et al., 2003; Ohgaki and Kleihues, 2005) . All current treatments for glioma, including surgery, radiotherapy and chemotherapy, ultimately fail to control the progressive spread and recurrence of this lethal class of brain tumor (Demuth and Berens, 2004) .
The migration and invasion inhibitor protein (MIIP) gene is an inhibitor of migration and invasion in gliomas. It is located in the chromosome 1p36 region and contains 10 exons that span 12.6 kb of genomic DNA. MIIP encodes a protein of 388 amino acids, with a predicted molecular weight of 43 kDa. The 1p36 region is deleted in 25-81% of cases in a wide spectrum of human cancers (Gibbs et al., 1999; Ragnarsson et al., 1999; Smith et al., 1999; Janoueix-Lerosey et al., 2004; Fujita et al., 2008; Munirajan et al., 2008) .
Our group initially discovered the MIIP gene and demonstrated that its protein expression is reduced or undetectable in some glioblastoma samples. Our further studies showed that the MIIP protein inhibits the migration and invasion of glioma cells by binding to and inhibiting the invasion-enhancing oncogene product insulin-like growth factor binding protein 2 (IGFBP2) (Song et al., 2003) . Recently we reported that MIIP regulates HDAC6 activity and increases acetylated alpha-tubulin (Wu et al., 2010) . A single nucleotide polymorphism of MIIP affects the risk of breast cancer . In this study, we investigated the effect of MIIP on gliomagenesis both in vitro and in a glial-specific transgenic mouse model, which led to the identification of previously unrecognized roles for MIIP in the attenuation of mitotic transition and in the inhibition of glioma development and progression.
Results

MIIP inhibits tumorigenicity of glioma cells in vitro
We initially discovered MIIP as an inhibitor of cellular migration and invasion gene (Song et al., 2003) . The expression of MIIP was reduced or undetectable at the protein level in some glioblastoma tumor tissue samples (Song et al., 2003) . To understand the effect of MIIP on gliomagenesis, we first used a gain-of-function (transfection) method to modulate MIIP expression in glioma cells. MIIP protein overexpression was readily detected in transfected glioma cells (Figure 1a ). The glioma cell lines, LN229, U87, U251 and U373, were transfected with either the MIIP construct or the control vector, and subsequently cultured in the presence of 200 mg/ml hygromycin. MIIP overexpression resulted in a significant reduction in colony formation in all four glioma cell lines (Figures 1b and c) . In addition, we found that the MIIP expression markedly reduced colony formation in HCT116 colon, HEC 1A and HEC 1B endometrial and MCF7 breast cancer cell lines (Ji P, unpublished results), indicating that MIIP has broad inhibitory effects among different cancer types.
We also evaluated the effect of MIIP on glioma cell growth by measuring the growth curve of glioma cells after modulation of MIIP levels. We transfected the MIIP expression construct into LN229 cells and obtained LN229 clones after 4 weeks of selection that express increased levels of MIIP (Figure 1d , upper panel). Cell growth assay was performed to quantify the growth rate in the three MIIP-overexpressing clones (termed M1, M2 and M3), two vector control clones (V1 and V2) and the parental cell line. MIIP-overexpressing clones had retarded cell growth rate (Figure 1d , lower panel). Among the glioma cells we tested, the SNB19 line has a relatively higher level of endogenous MIIP. Next, we used MIIP small interfering RNA to knock down the endogenous MIIP expression in SNB19 cells (Figure 1e ). The cell growth curve showed that decreased MIIP expression in SNB19 resulted in increased cell growth (P ¼ 0.046, Figure 1e ).
MIIP expression inhibits glioma development and progression in a glial-specific transgenic mouse model To show that MIIP has an important role in the inhibition of gliomagenesis in vivo, we used a powerful glial-specific transgenic mouse model (RCAS-N-tva). In this model, mice that harbor a transgene construct with nestin-promoter-driven glial-specific expression of an avian viral receptor (tva) are used as recipients (N-tva mice). Replication-competent avian leukemia virus splice acceptor (RCAS) vectors that carry specific genes of interest are injected into the cortex of newborn N-tva mice (Holland et al., 1998) . Tumor incidence and grade can be evaluated within 13 weeks after injection. In a recent study, we reported that delivery of the plateletderived growth factor b-gene (PDGFB) alone into these transgenic mice resulted in a high incidence (490%) of low-grade oligodendroglioma, and the combination of PDGFB and IGFBP2 resulted in advanced anaplastic oligodendroglioma in nearly half of the cases (with an overall incidence 496%) (Dunlap et al., 2007) .
To explore whether MIIP has a role in gliomagenesis in the RCAS-N-tva mouse model, we cloned MIIP into the RCAS vector and codelivered MIIP with PDGFB, or with both PDGFB and IGFBP2, into the RCAS-Ntva mouse model and monitored the resulting tumor phenotype. Thirteen weeks after the injection, or at the first sign of distress/disease, all mice were killed and tumor histopathology was evaluated. The results show that MIIP reduces the PDGFB-driven oligodendroglioma rate from 90 to 64%, and also reduces the PDGFB-IGFBP2 driven glioma rate from 97 to 68%. Furthermore, MIIP codelivery with PDGFB-IGFBP2 significantly blocks IGFBP2-induced progression to anaplastic oligodendroglioma, reducing this rate from 38 to 4% (Table 1 , Figure 2 ).
Expression of MIIP attenuates mitotic transition
We next focused our attention on understanding the mechanism by which MIIP functions. First, stable LN229-MIIP cells and stable LN229-control cells were synchronized at the G 1 /S boundary using a double thymidine block. The cells were then switched to a standard culture medium to allow progression through the G 1 /S boundary. The proliferating cells with new DNA synthesis were measured using a BrdU (5-bromo-2-deoxyuridine)-incorporation assay, whereby the cells with newly synthesized DNA are labeled with fluorescein isothiocyanate (FITC)-conjugated anti-BrdU antibody. The cell-cycle stage was determined by propidium iodide staining, which measures DNA content. The results showed that overexpression of MIIP did not significantly affect either the G 1 /S transition or DNA replication ( Figure 3a) . Next, the stable LN229-MIIP and LN229-control cells were synchronized at prometaphase by nocodazole treatment. The synchronized cells were then released and harvested at sequential time points. Flow cytometry analysis showed that MIIP expression significantly delayed G 2 / M transition ( Figure 3b ). To further distinguish whether overexpression of MIIP results in G 2 /M arrest or attenuation of mitotic transition, the stable LN229-MIIP and LN229-control cells were synchronized by nocodazole treatment. Mitotic cells collected by the shake-off method were released for the times indicated, labeled with FITC-conjugated anti-phospho-histone H3 (pHH3, a mitosis-specific marker) antibody, stained with propidium iodide and then measured by flow cytometry. The results showed that cells with MIIP overexpression had a slower rate of reduction of the mitotic population (pHH3-positive cells) compared with control cells (Figures 3c and d) . These results provide evidence that MIIP negatively regulates mitotic transition in the cell cycle.
MIIP interacts with Cdc20 and blocks APC/C Cdc20 activity It is well known that mitotic transition is regulated by APC/C ubiquitin-ligase E3 activity. Cdc20 and Cdh1 are two substrate-specific adaptors and activators of the ubiquitin-ligase APC/C complex (Yu, 2007) . Cdc20 activates APC/C from the onset of mitosis, whereas Abbreviations: IGFBP2, insulin-like growth factor binding protein 2; MIIP, migration and invasion inhibitor protein; PDGFB, platelet-derived growth factor-b; RCAS, replication-competent avian leukemia virus splice acceptor. Tumor histopathology was evaluated by a board-certified neuropathologist (GNF). Anaplastic oligodendroglioma was distinguished from lowgrade oligodendroglioma on the basis of the presence of the following features in anaplastic oligodendroglioma: brisk mitotic activity, foci of microvascular proliferation and foci of tumor necrosis. Cdh1 activates APC/C in the G 1 phase. As we showed that MIIP regulates mitotic transition, we next examined whether MIIP binds Cdc20, thereby diminishing APC/C ubiquitin-ligase activity and attenuating mitotic transition. We first cotransfected embryonal kidney 293FT cells with an HA-tagged Cdc20 expression construct and a FLAG-tagged MIIP construct. An unrelated FLAG-tagged neutrophil gelatinase-associated lipocalin (NGAL) construct was used as a negative control for this experiment. We found that Cdc20 specifically copurified with MIIP in an immunoprecipitation assay (Figure 4a ). Both Cdc20 and Cdh1 are APC/C ubiquitin-ligase E3 activators, and there are common binding sites (such as D box) with target proteins, but Cdh1 has a more relaxed binding specificity (Fang et al., 1998; Yamano et al., 2004) . To understand whether MIIP is a specific binding protein for Cdc20, we assessed whether MIIP could coimmunoprecipitate with Cdh1. An expression vector containing either FLAG-tagged MIIP or FLAG-tagged NGAL (as a negative control) was transfected into 293FT cells, and a coimmunoprecipitation assay was performed using anti-FLAG M2 agarose beads, followed by immunoblotting with either an anti-Cdc20 or antiCdh1 antibody. This experiment showed that under standard conditions, Cdh1, unlike Cdc20, was undetectable in the pull-down complex containing FLAG-tagged MIIP (Figure 4b ). Furthermore, we performed coimmunoprecipitation with MIIP antibody or Cdc20 antibody to determine the interaction in untransfected 293 FT cells, which demonstrated that endogenous MIIP and Cdc20 were indeed binding each other ( Figure 4c ). As Cdc20 is required for APC/C activity during mitosis, we hypothesized that the interaction of Cdc20 with MIIP would lead to reduced APC/C ubiquitinligase activity. To test this, we isolated the APC/C complex from Xenopus laevis extracts using anti-Cdc27 agarose beads and then incubated the complex with Cdc20 protein in the presence or absence of MIIP in equimolar amounts. Mad2 served as a negative control. An N-terminal 102 amino-acid fragment of cyclin B1 was used as a substrate for APC/C Cdc20 . We observed marked ubiquitination of cyclin B1 in the absence of MIIP; in contrast, a significant decrease in cyclin B1 ubiquitination in the presence of MIIP or Mad2 was observed (Figure 4d) . 
MIIP modulates cyclin B1 stability
The expression level of cyclin B1 controls the schedule of mitotic progression. Cyclin B1/Cdc2 activity is temporally regulated by cyclin B1 protein levels during the G 2 / M transition, the onset of anaphase and mitotic exit (Nilsson et al., 2008; Wolthuis et al., 2008 ). The steadystate level of cyclin B1 protein is regulated by the APC/ C ubiquitination and degradation system (Yamano et al., 2004; Homer et al., 2005) . Our results, shown in Figure 4d , suggest that MIIP regulates cellular cyclin B1 levels. First, we determined the protein kinetic change of MIIP and cyclin B1 during mitotic transition. Both LN229-MIIP and LN229-control stable cells were synchronized at the G1/S phase by double thymidine block, and the cells were released in fresh medium at the indicated time; at the 10 h time point, 490% of the cells were in mitosis, and the protein level of cyclin B1 correlated with that of MIIP, even at the 12 h time point (Figure 5a ). We also transiently transfected the MIIP construct into LN229 cells and found that the increasing cyclin B1 protein level was associated with increasing levels of MIIP (Figure 5b ). In reverse, we subsequently performed MIIP small interfering RNA knockdown experiments in HEK cells, HCT116 colon cancer cells and SNB19 glioma cells. We observed reduced cyclin B1 protein levels in all of the MIIP-knockdown cells (Figure 5c ). In contrast, the Cdc20 and actin levels in the small interfering RNA-treated cells did not change. In summary, we demonstrated that MIIP modulates cyclin B1 protein levels in all cancer cell lines tested.
MIIP induces mitotic catastrophe of glioma cells
Finally, we examined the consequence of attenuation of mitotic transition by MIIP. The FLAG-tagged MIIP construct was transiently transfected into LN229 glioma cells for 72 h to allow MIIP expression in the cells. MIIP-positive cells were recognized by anti-FLAG antibody and labeled with FITC-conjugated secondary antibody; Cdc20 was labeled with phycoerythrin-conjugated secondary antibody; chromosomal DNA was stained with DAPI ( Figure 6a ). More than 200 mitotic cells were counted under immuofluorescence microscopy; 42 MIIP-positive mitotic cells were detected. In the MIIP-positive population of cells, 450% exhibited abnormal chromosome morphology, such as lagged chromosome, chromotid breaks or multiradial configurations. In contrast, only 10% of cells with abnormal chromosomes were detected in MIIP-negative cells (Figure 6b ).
Discussion
In this study, we show that MIIP significantly inhibits gliomagenesis in vitro and in vivo, and we identify a . When overexpressed, MIIP maintains cellular cyclin B1, resulting in the attenuation of mitotic transition, and increased mitotic catastrophe in glioma cells, which is consistent with the tumor-suppression function we observed in vitro and in vivo.
These results support the hypothesis that MIIP serves a tumor-suppression function through monitoring of mitosis. This notion is consistent with genetic results showing that the MIIP gene, located on chromosomal region 1p36, is commonly deleted (one copy) in a wide spectrum of human cancers, including gliomas (Smith et al., 1999) , neuroblastoma (Fujita et al., 2008) , prostate carcinoma (Gibbs et al., 1999) , breast carcinoma, ovarian carcinoma, melanoma and several types of sarcomas (Ragnarsson et al., 1999) . MIIP expression is reduced or undetectable in high-grade gliomas (Song et al., 2005) . On the other hand, mitosis is a normal cellular function and any drastic alteration could lead to cellular lethality; this is consistent with the observation that we did not detect homozygous deletion and/or mutation of MIIP in glioblastoma multiforme tumor tissue samples or glioma cell lines. Therefore, it is not surprising that MIIP behaves more like other negative cell-cycle regulators, such as p21, and less like classical tumor suppressors, such as TP53. Hence, the growth inhibitory effect of MIIP is more subtle and tumor type dependent. The tumor suppression effect of MIIP is obvious in the RCAS-N-tva glial-specific transgenic mouse model that we used. Codelivery of MIIP with PDGFB, or with both PDGFB and IGFBP2, into N-tva mice reduced glioma incidence from 90 to 64%, and from 97 to 68%, respectively. MIIP codelivery with IGFBP2 significantly blocked glioma progression from low-grade (oligodendroglioma) to high-grade (anaplastic oligodendroglioma), reducing the incidence of highgrade tumors from 38 to 4%. Thus, MIIP may have a stronger effect on high-grade gliomas, which have more genetic and cell-cycle defects. In this sense, MIIP may also serve as a 'guardian of the genome' that preferentially weeds out the most damaged cells.
The mitotic checkpoint is an evolutionarily conserved mechanism that ensures that cells exiting mitosis have accurately aligned and separated chromosomes. This is an important gate-keeping mechanism for genome stability. Cyclin B/Cdc2 is one of the major regulators of the mitotic process, and its activity is precisely controlled temporally and spatially by the APC/C ubiquitin and degradation system. Many mitotic checkpoint proteins (such as Mad1-3 and Bub1-3) (Li and Benezra, 1996; Fraschini et al., 1999) and other regulatory proteins (such as Emi1 and RASSF1) modulate APC/C Cdc20 activity in different types of cancer cells (Reimann et al., 2001; Song et al., 2004; Miller et al., 2006) . Our studies have provided evidence that MIIP may be an important regulatory molecule for this critical checkpoint. Future studies are required to further characterize MIIP modulation of this important cellular checkpoint, and how altered regulation contributes to cancer development and progression.
Materials and methods
Reagents and plasmids
Thymidine, nocodazole, anti-Cdc27 (APC3) antibody, antiactin antibody, anti-FLAG antibody, 3 Â FLAG peptide and anti-FLAG M2 agarose beads were purchased from Sigma-Aldrich (St Louis, MO, USA). Antibodies for cyclin B1 and Cdc2 were obtained from Cell Signaling Technology (Danvers, MA, USA). Anti-Cdc27 agarose beads and antibodies directed against pHH3 (Ser10), Cdc20 and tubulin were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Anti-Cdh1 antibody was purchased from NeoMarkers (Fremont, CA, USA). A rabbit polyclonal antibody raised against an MIIP epitope was generated by Bethyl Laboratories (Montgomery, TX, USA) (Song et al., 2003) . Small interfering RNA for MIIP and the nontargeting control were acquired from Ambion (Foster City, CA, USA). The MIIP gene fused with a C-terminal FLAG tag and GFP were cloned into the pcDNA3.1/hygromycin vector (Invitrogen). The transfection reagents Lipofectamine 2000 and Lipofectamine RNAiMAX, and the propidium iodide solution were purchased from Invitrogen (Carlsbad, CA, USA). The RCAS constructs containing IGFBP2 and MIIP were generated in our laboratory using standard molecular cloning techniques, and the RCAS vectors containing PDGFB and GFP were generously provided by Dr Eric Holland (Memorial SloanKettering, New York, NY, USA) and Dr Yi Li (Baylor College of Medicine, Houston, TX, USA), respectively.
Cell synchronization and cell-cycle assay by flow cytometry Glioma cells were synchronized at the G 1 /S boundary using a double thymidine block (2 mM) as described previously (Peschiaroli et al., 2006) . Synchronization in prometaphase with 100 ng/ml nocodazole for 16 h and mitotic shake-off were performed. The cells were released from G 1 /S or prometaphase at indicated times, fixed with 70% ethanol and stained with propidium iodide. The cell-cycle distribution was measured by flow cytometry.
Mitotic index assay by flow cytometry
The cells were synchronized at prometaphase by 100 ng/ml nocodazole for 16 h; the mitotic cells obtained by the shake-off method were released in fresh media for the times indicated, blocked with phosphate-buffered saline (PBS) with 0.5% Tween-20 plus 1 mg/ml goat IgG, labeled with FITCconjugated anti-pHH3 (Ser10) antibody and stained by propidium iodide. Phospho-histone H3-positive cells were counted by flow cytometry, and the mitotic index was calculated by counting the number of cells in mitosis and dividing by the total number of cells.
Coimmunoprecipitation assay and western blotting
The immunoprecipitation assay was performed using anti-FLAG M2 agarose beads, or anti-HA agarose beads, or protein A/G beads, according to the manufacturer's instructions. Briefly, 300 mg of the 293 FT cell lysates were incubated with 10 ml beads conjugated with specific antibodies overnight. The pull-down complex was eluted with elution buffer with 3 xFLAG peptide or HA peptide. The pull-down complex was analyzed by western blotting. To quantify the level of protein expression, the density of protein bands from western blotting was imaged by Kodak 2000 (Kodak, Rochester, NY, USA) and the relative expression was normalized to the level of tubulin or b-actin.
Ubiquitination assay
The purified Cdc20 and MIIP proteins (or Mad2) were mixed in a 1:1 molar ratio for 1 h on ice and incubated with the APC/C complex purified from X. laevis extract. The 102 amino-acid N-terminal portion of cyclin B1 served as a substrate for APC/C. The in vitro APC/C-ubiquitination assay was performed as described previously (Tang et al., 2004) .
Immunofluorescence assay A total of 5 Â 10 4 LN229 cells in a total of 1 ml medium were seeded in a 4-well chamber slide overnight, transfected with FLAG-tagged MIIP construct by Lipofectamine 2000 for 48 h, then the cells were fixed with 200 ml freshly prepared 3.7% formaldehyde in PBS for 20 min at room temperature. The cells were washed with PBS twice and permeabilized by incubation at room temperature for 15 min with PBS/1% goat serum/0.5% Triton X-100. The cells were incubated with anti-FLAG antibody for 1 h. After incubating with FITCconjugated goat anti-mouse IgG for an additional hour, the cells were costained with DAPI for 30 min and observed under fluorescence microscopy.
RCAS mouse model and brain section staining
The RCAS mouse model experiments were approved by the Institutional Animal Care and Use Committee at The University of Texas MD Anderson Cancer Center and performed as described previously (Dunlap et al., 2007) . Briefly, DF-1 cells were grown in Dulbecco's modified Eagle's medium with 10% fetal bovine serum in a humidified incubator containing 5% CO 2 at 39 1C. DF-1 cells were transfected with the following RCAS constructs: PDGFB, GFP, IGFBP2 or MIIP, using the Nucleofector transfection system (Amaxa, Walkersville, MD, USA) according to the manufacturer's protocol. DF-1 cells containing RCAS virions were trypsinized, pelleted by centrifugation, resuspended in minimal PBS and injected into the right cortex of newborn N-tva transgenic mice. Mice were killed at 13 weeks of age (or before because of symptoms, and brain sectioning and hematoxylin and eosin staining were performed as described previously (Dunlap et al., 2007) . Anaplastic oligodendroglioma is characterized by the appearance of prominently increased mitotic activity, microvascular proliferation and foci of necrosis, as assessed by microscopic examination of hematoxylin and eosin-stained tissue sections.
